Latest International AIDS Vaccine Initiative Stories
ATLANTA, Oct. 18 /PRNewswire/ -- Robert T. McNally, Ph.D., president and CEO of GeoVax Labs, Inc.
SHANGHAI, Oct. 17 /PRNewswire-Asia/ -- At the end of 2009, the vaccine industry raised so much concern worldwide that the headlines of the business media were occupied by various kinds of news about vaccine enterprises. For example, Sinovac Biotech Co., Ltd.
ATLANTA, Oct. 1 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc.
As researchers and policymakers work toward an effective HIV vaccine in a constrained global economy, cost-effective prevention strategies such as Couples Voluntary Counseling and Testing (CVCT) must take a larger role in efforts to decrease the rates of HIV/AIDS in Africa, says Emory University HIV/AIDS vaccine researcher Susan Allen, MD, MPH.
ATLANTA, Sept. 27 /PRNewswire/ -- Harriet L. Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc.
NEW YORK, Sept.
ATLANTA, Sept. 7 /PRNewswire/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announces that Chief Executive Officer Dr.
ATLANTA, Aug. 27 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc.
ROCKVILLE, Md., Aug. 17 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that the company will be presenting at the IMVAC Summit. The Conference will take place August 17-19, 2010 at the Royal Sonesta Hotel, Cambridge, MA. Dr.
Black Treatment Advocates Network (BTAN) Focuses on Improving Care for Thousands of Black Americans in the U.S. WHITEHOUSE STATION, N.J. and LOS ANGELES, Calif., Aug.
- An interdisciplinary study of social injustice.